In MDS, SF3B1 mutations are present at frequencies of 20%−30% and are associated with the presence of ring sideroblasts and with favorable clinical outcomes and a lower incidence of leukemia [25–27]. Here, SF3B1 is linked to myelodysplastic syndrome.